Which has stronger valuation & earnings, SCPS or ARDS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.31 0.00

Is SCPS or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Is SMFL or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Smart for Life N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Is ARDS or NAVB more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A

Which has higher valuation & earnings, PXMD or ARDS?

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.31 0.00

Is PXMD or ARDS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Aridis Pharmaceuticals N/A N/A N/A

Do analysts recommend ARDS or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aridis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Aridis Pharmaceuticals (ARDS) Competitors

$0.0001 0.00 (0.00%)

As of 09/3/2026 03:19 PM Eastern

Compare

ARDS vs. SCPS, SMFL, NAVB, PXMD, and ADTX

Should you buy Aridis Pharmaceuticals stock or one of its competitors? Aridis Pharmaceuticals's main competitors and comparable companies include Scopus BioPharma (SCPS), Smart for Life (SMFL), Navidea Biopharmaceuticals (NAVB), PaxMedica (PXMD), and Aditxt (ADTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Aridis Pharmaceuticals	Neutral

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Scopus BioPharma has a beta of -0.19, meaning that its stock price is 119% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.66, meaning that its stock price is 4,866% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

Summary

Aridis Pharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Smart for Life	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Smart for Life. Smart for Life's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Smart for Life	Neutral
Aridis Pharmaceuticals	Neutral

Smart for Life has higher revenue and earnings than Aridis Pharmaceuticals. Smart for Life is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00

Smart for Life has a beta of 15.1, meaning that its share price is 1,410% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.66, meaning that its share price is 4,866% more volatile than the broader market.

Summary

Smart for Life and Aridis Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Navidea Biopharmaceuticals	Neutral

Aridis Pharmaceuticals has a beta of 49.66, indicating that its share price is 4,866% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market.

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Summary

Aridis Pharmaceuticals beats Navidea Biopharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Aridis Pharmaceuticals	N/A	N/A	N/A

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for PaxMedica. PaxMedica's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Aridis Pharmaceuticals	Neutral

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.66, meaning that its share price is 4,866% more volatile than the broader market.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats PaxMedica on 8 of the 9 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Aditxt?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Aridis Pharmaceuticals has a beta of 49.66, suggesting that its share price is 4,866% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aridis Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aridis Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aridis Pharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Aditxt	-360,152.50%	-374.60%	-105.93%

In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Aditxt. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Aditxt. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Aditxt	Neutral

Summary

Aridis Pharmaceuticals beats Aditxt on 9 of the 12 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDS vs. The Competition

Export

Metric	Aridis Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.29	25.25
Price / Sales	N/A	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	N/A	12.33	12.92	6.14
Net Income	-$30.37M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.60%	0.60%	-0.27%
1 Month Performance	N/A	6.96%	5.72%	0.68%
1 Year Performance	N/A	9.45%	25.33%	14.84%

Aridis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	+0.0%	$5K	N/A	0.00	30
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$17K	N/A	N/A	9
SMFL Smart for Life	N/A	N/A	N/A	-92.6%	$14K	$11.11M	N/A	110	Gap Down
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$8K	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. SCPS, SMFL, NAVB, PXMD, and ADTX

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Summary

How does Aridis Pharmaceuticals compare to Smart for Life?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Summary

How does Aridis Pharmaceuticals compare to PaxMedica?

Summary

How does Aridis Pharmaceuticals compare to Aditxt?

Summary

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. SCPS, SMFL, NAVB, PXMD, and ADTX

How does Aridis Pharmaceuticals compare to Scopus BioPharma?

Does the media favor SCPS or ARDS?

Do institutionals and insiders have more ownership in SCPS or ARDS?

Which has more risk & volatility, SCPS or ARDS?

Which has stronger valuation & earnings, SCPS or ARDS?

Is SCPS or ARDS more profitable?

Summary

How does Aridis Pharmaceuticals compare to Smart for Life?

Do institutionals and insiders hold more shares of SMFL or ARDS?

Is SMFL or ARDS more profitable?

Does the media refer more to SMFL or ARDS?

Which has stronger valuation and earnings, SMFL or ARDS?

Which has more volatility and risk, SMFL or ARDS?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Do institutionals & insiders have more ownership in ARDS or NAVB?

Is ARDS or NAVB more profitable?

Does the media refer more to ARDS or NAVB?

Which has more risk & volatility, ARDS or NAVB?

Which has stronger earnings & valuation, ARDS or NAVB?

Summary

How does Aridis Pharmaceuticals compare to PaxMedica?

Is PXMD or ARDS more profitable?

Does the media favor PXMD or ARDS?

Which has higher valuation & earnings, PXMD or ARDS?

Which has more volatility & risk, PXMD or ARDS?

Do institutionals & insiders have more ownership in PXMD or ARDS?

Summary

How does Aridis Pharmaceuticals compare to Aditxt?

Which has more volatility and risk, ARDS or ADTX?

Do institutionals & insiders have more ownership in ARDS or ADTX?

Which has better earnings and valuation, ARDS or ADTX?

Do analysts recommend ARDS or ADTX?

Is ARDS or ADTX more profitable?

Does the media favor ARDS or ADTX?

Summary

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools